WallStSmart

Gilead Sciences Inc (GILD)vsMP Materials Corp (MP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Gilead Sciences Inc generates 10589% more annual revenue ($29.44B vs $275.46M). GILD leads profitability with a 28.9% profit margin vs -31.2%. GILD earns a higher WallStSmart Score of 72/100 (B).

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 10.0Quality: 5.5
Piotroski: 6/9

MP

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 4/9Altman Z: 1.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GILDUndervalued (+53.9%)

Margin of Safety

+53.9%

Fair Value

$299.95

Current Price

$138.26

$161.69 discount

UndervaluedFair: $299.95Overvalued

Intrinsic value data unavailable for MP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$171.45B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

MP1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
70.0%10/10

Revenue surging 70.0% year-over-year

Areas to Watch

GILD1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

MP4 concerns · Avg: 2.0/10
Return on EquityProfitability
-5.0%2/10

ROE of -5.0% — below average capital efficiency

EPS GrowthGrowth
-55.6%2/10

Earnings declined 55.6%

Free Cash FlowQuality
$-109.26M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.132/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bull Case : MP

The strongest argument for MP centers on Revenue Growth. Revenue growth of 70.0% demonstrates continued momentum.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth.

Bear Case : MP

The primary concerns for MP are Return on Equity, EPS Growth, Free Cash Flow.

Key Dynamics to Monitor

GILD profiles as a value stock while MP is a hypergrowth play — different risk/reward profiles.

MP carries more volatility with a beta of 1.62 — expect wider price swings.

MP is growing revenue faster at 70.0% — sustainability is the question.

GILD generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

GILD scores higher overall (72/100 vs 29/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

MP Materials Corp

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

MP Materials Corp. The company is headquartered in Las Vegas, Nevada.

Want to dig deeper into these stocks?